Welcome to our dedicated page for Synaptogenix SEC filings (Ticker: SNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Synaptogenix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Synaptogenix's regulatory disclosures and financial reporting.
Synaptogenix, Inc. (Nasdaq: SNPX) filed an 8-K on June 24, 2025 disclosing two related developments under Items 7.01 and 8.01.
First, the Company executed its initial purchase of the cryptocurrency “TAO” as the opening step in a previously announced digital-asset treasury strategy. Funding for the acquisition came directly from existing cash on the balance sheet; no external financing or equity issuance was mentioned.
Second, Synaptogenix appointed BitGo Trust Company, Inc. as its qualified custodian and trading partner. BitGo will (1) hold the Company’s TAO in regulated, insured cold storage, (2) facilitate additional TAO purchases via its platforms and OTC desk, and (3) enable TAO to be staked directly from custody. Management states that staking has already begun to generate revenue, positioning the digital-asset holdings as an income-producing treasury component while maintaining security and compliance.
No dollar amounts, number of tokens, staking yields, or risk-management parameters were provided in the filing. A press release containing the same information was furnished as Exhibit 99.1 and is expressly not incorporated by reference into Exchange Act filings.
Key investor takeaways:
- Synaptogenix is now exposed to cryptocurrency price volatility and operational risks.
- The partnership with a regulated custodian and the revenue-generating staking model signal an intent to treat TAO as a strategic, yield-bearing asset rather than a passive holding.
- Absence of quantitative disclosures limits assessment of materiality at this stage.
Synaptogenix has filed Form D for a completed offering of securities under Rule 506(b) of Regulation D. The biotechnology company raised $5.5 million through the sale of equity securities and warrants to 5 investors, with the offering closing on June 23, 2025.
Key details of the offering:
- Sales commissions totaled $385,000, paid to GP Nurmenkari Inc.
- Securities were offered in Illinois, New York, and Ohio
- The offering duration is less than one year
- No minimum investment requirement was specified
Company leadership includes Joshua Silverman as Executive Chairman, Robert Weinstein as CFO, and directors William Singer, Bruce T. Bernstein, and Jonathan L. Schechter. The company is headquartered in New York and was incorporated in Delaware over five years ago.